Latest Breaking News On - Hyesung shin - Page 1 : comparemela.com

Aptabio s Isuzinaxib (APX-115) proves its effect on a key kidney function marker in a Phase 2 clinical study in patients with diabetes and chronic kidney.

United statesSouth koreaPrnewswire aptabioHyesung shinDae ryong chaCenters for diseaseKorea university college of medicineHuman servicesDrug development companyPlatform technologyAptabio therapeutics incAmerican society of nephrologyUs department of healthUrine albumin creatine ratioIsuzinaxib phaseAmerican society